[Cyclooxygenase 2 inhibitors and colorectal cancer]

Marianne Bernardeau-Mozer1, Stanislas Chaussade

  • 1Service d'Hépato-gastroentérologie Pavilion Achard 9e, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75014 Paris.

Bulletin Du Cancer
|July 9, 2004
PubMed

Insights

Cyclooxygenase-2 (Cox2) is overexpressed in most colorectal tumors and drives cancer growth. Cox2 inhibitors show promise for preventing and treating colorectal cancer, especially in high-risk individuals.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Context:

  • Cyclooxygenase-2 (Cox2) is an inducible enzyme overexpressed in 80% of colorectal tumors.
  • Cox2 plays a critical role in colorectal tumorigenesis by inhibiting apoptosis, promoting cellular proliferation, and inducing angiogenesis.

Purpose:

  • To review the relationship between Cox2/Cox2 inhibitors and colorectal carcinogenesis signaling pathways.
  • To clarify the molecular mechanisms of action for Cox2 inhibitors in colorectal cancer.

Summary:

  • Cox2 is a key molecular target in colorectal cancer management.
  • Cox2 inhibitors have demonstrated efficacy in animal studies and are approved for specific patient groups in humans.
  • This review examines clinical data on the chemopreventive and therapeutic efficacy of Cox2 inhibitors across various risk groups for colorectal cancer.

Impact:

  • Cox2 inhibitors represent a potential therapeutic strategy for colorectal cancer.
  • Understanding Cox2 signaling pathways can lead to improved chemopreventive and therapeutic interventions.
  • This review provides insights into the clinical utility of Cox2 inhibitors for colorectal cancer management.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...